Belpointe Asset Management’s VanEck Pharmaceutical ETF PPH Stock Holding History

Belpointe Asset Management’s Portfolio PPH Stock Details PPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.12M	Buy	10,229 +2,175	+27%	+$225K	0.04%	458
2026 Q1	$837K	Sell	8,054 -39	-0.5%	-$4.16K	0.03%	522
2025 Q4	$835K	Sell	8,093 -20	-0.2%	-$1.95K	0.03%	498
2025 Q3	$733K	Buy	8,113 +2,409	+42%	+$211K	0.03%	504
2025 Q2	$502K	Sell	5,704 -93	-2%	-$8.06K	0.02%	574
2025 Q1	$528K	Buy	+5,797	New	+$522K	0.03%	550
2023 Q2	–	Sell	-120	Closed	-$9.32K	–	2614
2023 Q1	$9.32K	Sell	120 -167	-58%	-$12.9K	﹤0.01%	2755
2022 Q4	$22.3K	Buy	+287	New	+$21.2K	﹤0.01%	2106

Other funds holding PPH

AWC

Adamsbrown Wealth Consultants Wichita, Kansas $530M AUM 23.21% 1-Year Est. Return

RBC

Rye Brook Capital Greenwich, Connecticut $143M AUM 33.65% 1-Year Est. Return

WWM

WT Wealth Management Scottsdale, Arizona $361M AUM 23.03% 1-Year Est. Return

Fluent Financial Dallas, Texas $280M AUM 16.1% 1-Year Est. Return

AWMT

AAFMAA Wealth Management & Trust Fayetteville, North Carolina $286M AUM 19.57% 1-Year Est. Return

CWRP

Cassady Wealth & Retirement Planning Henderson, Nevada $215M AUM

AWM

Avior Wealth Management Omaha, Nebraska $3.8B AUM 23.28% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

AWA

ARQ Wealth Advisors Scottsdale, Arizona $807M AUM 19.58% 1-Year Est. Return

AWM

Axxcess Wealth Management Carlsbad, California $6.28B AUM 24.26% 1-Year Est. Return

Belpointe Asset Management's PPH Position: Q2 2026 in Review

Belpointe Asset Management increased its VanEck Pharmaceutical ETF (PPH) stake by 27% in Q2 2026, buying an estimated $225K and bringing the position to 10,229 shares worth $1.12M. The position accounts for 0.04% of the portfolio, ranked #458.

Belpointe Asset Management first reported a position in PPH in Q4 2022 and has held it in 8 quarters since. 47 funds tracked by Wall St. Rank hold PPH as of Q2 2026.

Belpointe Asset Management held 10,229 shares of VanEck Pharmaceutical ETF worth $1.12M as of Q2 2026.
Belpointe Asset Management bought 2,175 VanEck Pharmaceutical ETF shares in Q2 2026, an estimated $225K.
VanEck Pharmaceutical ETF made up 0.04% of Belpointe Asset Management's portfolio in Q2 2026, its #458 holding.
Belpointe Asset Management first reported a position in VanEck Pharmaceutical ETF in Q4 2022 and has held it in 8 quarters since.
47 funds tracked by Wall St. Rank held VanEck Pharmaceutical ETF as of Q2 2026.

Based on Belpointe Asset Management's 13F filing for Q2 2026, filed 31 Jul 2026.